{"title":"放松疗法对有医学上无法解释症状患者苯二氮卓类药物使用的影响。","authors":"Kazuaki Hashimoto, Takeaki Takeuchi, Akiko Koyama, Miki Hiiragi, Shunsuke Suka, Masahiro Hashizume","doi":"10.1186/s13030-020-00187-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The change in the benzodiazepine (BZD) use of patients with medically unexplained symptoms (MUS) following the application of relaxation therapy were examined.</p><p><strong>Methods: </strong>Of the 221 outpatients with MUS using BZD, 42 received relaxation therapy. Change in BZD use was compared using a relaxation group (<i>n</i> = 42) and a control group that had 84 MUS patients whose baseline was matched by optimal matching algorithms. Logistic regression analysis was done to evaluate the effect of BZD-dependent factors on the BZD dose of the relaxation group.</p><p><strong>Results: </strong>Compared with the control group, the number of patients who decreased the amount of BZD and the number of patients whose subjective symptoms of MUS improved were significantly higher in the relaxation group (<i>p</i> < 0.05). In addition, a factor that made it difficult to reduce the BZD of MUS patients who had undergone relaxation was a long history of BZD use, for more than 6 months (odds ratio, 0.06, 95% confidence interval, 0.01-0.36).</p><p><strong>Conclusions: </strong>Relaxation therapy for patients with MUS may help reduce BZD use; however, early intervention is important to prevent BZD dependence.</p>","PeriodicalId":9027,"journal":{"name":"BioPsychoSocial Medicine","volume":"14 ","pages":"13"},"PeriodicalIF":2.3000,"publicationDate":"2020-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13030-020-00187-7","citationCount":"3","resultStr":"{\"title\":\"Effect of relaxation therapy on benzodiazepine use in patients with medically unexplained symptoms.\",\"authors\":\"Kazuaki Hashimoto, Takeaki Takeuchi, Akiko Koyama, Miki Hiiragi, Shunsuke Suka, Masahiro Hashizume\",\"doi\":\"10.1186/s13030-020-00187-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The change in the benzodiazepine (BZD) use of patients with medically unexplained symptoms (MUS) following the application of relaxation therapy were examined.</p><p><strong>Methods: </strong>Of the 221 outpatients with MUS using BZD, 42 received relaxation therapy. Change in BZD use was compared using a relaxation group (<i>n</i> = 42) and a control group that had 84 MUS patients whose baseline was matched by optimal matching algorithms. Logistic regression analysis was done to evaluate the effect of BZD-dependent factors on the BZD dose of the relaxation group.</p><p><strong>Results: </strong>Compared with the control group, the number of patients who decreased the amount of BZD and the number of patients whose subjective symptoms of MUS improved were significantly higher in the relaxation group (<i>p</i> < 0.05). In addition, a factor that made it difficult to reduce the BZD of MUS patients who had undergone relaxation was a long history of BZD use, for more than 6 months (odds ratio, 0.06, 95% confidence interval, 0.01-0.36).</p><p><strong>Conclusions: </strong>Relaxation therapy for patients with MUS may help reduce BZD use; however, early intervention is important to prevent BZD dependence.</p>\",\"PeriodicalId\":9027,\"journal\":{\"name\":\"BioPsychoSocial Medicine\",\"volume\":\"14 \",\"pages\":\"13\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2020-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s13030-020-00187-7\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BioPsychoSocial Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13030-020-00187-7\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioPsychoSocial Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13030-020-00187-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Effect of relaxation therapy on benzodiazepine use in patients with medically unexplained symptoms.
Background: The change in the benzodiazepine (BZD) use of patients with medically unexplained symptoms (MUS) following the application of relaxation therapy were examined.
Methods: Of the 221 outpatients with MUS using BZD, 42 received relaxation therapy. Change in BZD use was compared using a relaxation group (n = 42) and a control group that had 84 MUS patients whose baseline was matched by optimal matching algorithms. Logistic regression analysis was done to evaluate the effect of BZD-dependent factors on the BZD dose of the relaxation group.
Results: Compared with the control group, the number of patients who decreased the amount of BZD and the number of patients whose subjective symptoms of MUS improved were significantly higher in the relaxation group (p < 0.05). In addition, a factor that made it difficult to reduce the BZD of MUS patients who had undergone relaxation was a long history of BZD use, for more than 6 months (odds ratio, 0.06, 95% confidence interval, 0.01-0.36).
Conclusions: Relaxation therapy for patients with MUS may help reduce BZD use; however, early intervention is important to prevent BZD dependence.
期刊介绍:
BioPsychoSocial Medicine is an open access, peer-reviewed online journal that encompasses all aspects of the interrelationships between the biological, psychological, social, and behavioral factors of health and illness. BioPsychoSocial Medicine is the official journal of the Japanese Society of Psychosomatic Medicine, and publishes research on psychosomatic disorders and diseases that are characterized by objective organic changes and/or functional changes that could be induced, progressed, aggravated, or exacerbated by psychological, social, and/or behavioral factors and their associated psychosomatic treatments.